© Reuters. FILE PHOTO: A vial of Biontech-Pfizer’s Comirnaty vaccine against COVID-19 and syringes are seen during vaccination at the Institute for Health and Food Safety of Zenica, Bosnia and Herzegovina, December 16, 2021. REUTERS/Dado Ruvic/File photo
By Ludwig Burger
BERLIN (Reuters) – Shares in Germany’s BioNTech (NASDAQ:) fell on Monday after it flagged write-downs of up to 900 million euros ($947 million) reflecting similar charges its partner Pfizer (NYSE:) announced on their COVID-19 vaccine business last week.
Hit by a plunge in use of pandemic-related products, Pfizer on Friday said it would take $900 million in write-offs and other charges for their jointly developed Comirnaty vaccine, on top of much larger write-offs on Pfizer’s own COVID treatment Paxlovid.
For its third-quarter accounts, BioNTech will likely “recognise the effect of Pfizer’s inventory write-offs and other charges related to Comirnaty in the third quarter of 2023 up to 0.9 billion euros, which represents BioNTech’s half of the gross profit-sharing agreement with Pfizer,” it said in a statement.
Shares in the vaccine maker, which is also developing cancer treatments, were down 7% to a two-month low in Frankfurt as of 0756 GMT.
BioNTech, which relies on vaccine-related profit-sharing payments from its U.S. partner for much of its revenue, said the write-offs would also reduce its 2023 revenue.
A BioNTech spokesperson on Monday declined to comment on the company’s current 2023 outlook, which is for COVID-19 vaccine revenue of about 5 billion euros.
The company is scheduled to release detailed third-quarter figures on Nov. 6.
The company added that it had been told by Pfizer that most of the write-offs relate to raw materials, as well as to inventories of vaccine versions that are older than the upgraded one currently in use.
($1 = 0.9498 euros)
Read the full article here